PMID- 26261669
OWN - NLM
STAT- MEDLINE
DCOM- 20160516
LR  - 20181113
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 8
IP  - 6
DP  - 2015
TI  - Utility of immunohistochemistry with an antibody against MYC at the initial 
      diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive 
      clinical course: a case report and review of the literature.
PG  - 7559-64
AB  - Follicular lymphoma (FL) is the most common indolent lymphoma, and associated 
      with the chromosomal translocation t(14;18)(q32;q21). While, FL harboring both 
      BCL2 and MYC translocation at diagnosis is very rare. The evaluation of MYC 
      expression in typical FL at presentation using southern blot, G-banded 
      karyotyping or fluorescence in situ hybridization (FISH) analyses has been 
      described so far. However, there are no reports about the use of 
      immunohistochemistry (IHC) to evaluate MYC protein expression in FL at 
      presentation. Here, we present a FL patient who transformed to a B-cell lymphoma, 
      unclassifiable, with features intermediate between diffuse large B-cell lymphoma 
      and Burkitt's lymphoma, accompanied by concurrent BCL2, BCL6, and MYC 
      translocations; i.e., triple-hit lymphoma. Paraffin-embedded tissue section-FISH 
      analysis demonstrated that the FL was negative for MYC, but MYC protein 
      expression was subsequently detected in the lymph node specimen obtained at the 
      initial diagnosis using IHC. This case revealed aggressive clinical course and 
      central nervous system involvement. In the literature concerning MYC positive FL 
      five out of 8 patients were dead within 24 months. The detection of MYC protein 
      expression in FL using IHC might be useful to predict more aggressive clinical 
      course.
FAU - Ichikawa, Kunimoto
AU  - Ichikawa K
AD  - Department of Internal Medicine, Division of Hematology, Juntendo University 
      School of Medicine Tokyo, Japan ; Department of Hematology, Juntendo University 
      Urayasu Hospital Chiba, Japan.
FAU - Aritaka, Nanae
AU  - Aritaka N
AD  - Department of Hematology, Juntendo University Nerima Hospital Tokyo, Japan.
FAU - Ogura, Kanako
AU  - Ogura K
AD  - Department of Diagnostic Pathology, Juntendo University Nerima Hospital Tokyo, 
      Japan.
FAU - Hosone, Masaru
AU  - Hosone M
AD  - Department of Pathology, Nippon Medical School Tama-Nagayama Hospital Tokyo, 
      Japan.
FAU - Ota, Yasunori
AU  - Ota Y
AD  - Department of Pathology, Institute of Medical Science, The University of Tokyo 
      Tokyo, Japan.
FAU - Sato, Eriko
AU  - Sato E
AD  - Department of Hematology, Juntendo University Nerima Hospital Tokyo, Japan.
FAU - Komatsu, Norio
AU  - Komatsu N
AD  - Department of Internal Medicine, Division of Hematology, Juntendo University 
      School of Medicine Tokyo, Japan.
FAU - Hirano, Takao
AU  - Hirano T
AD  - Department of Hematology, Juntendo University Nerima Hospital Tokyo, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20150601
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (BCL2 protein, human)
RN  - 0 (BCL6 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - DNA-Binding Proteins/genetics
MH  - Disease Progression
MH  - Fatal Outcome
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - *Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, B-Cell/*chemistry/genetics/pathology
MH  - Lymphoma, Follicular/*chemistry/genetics/pathology
MH  - Neoplasm Grading
MH  - Phenotype
MH  - Predictive Value of Tests
MH  - Proto-Oncogene Proteins c-bcl-2/genetics
MH  - Proto-Oncogene Proteins c-bcl-6
MH  - Proto-Oncogene Proteins c-myc/*analysis/genetics
MH  - Time Factors
MH  - Translocation, Genetic
PMC - PMC4526003
OTO - NOTNLM
OT  - BCL2
OT  - BCL6
OT  - MYC
OT  - follicular lymphoma
OT  - transformation
OT  - triple-hit lymphoma
EDAT- 2015/08/12 06:00
MHDA- 2016/05/18 06:00
PMCR- 2015/06/01
CRDT- 2015/08/12 06:00
PHST- 2015/04/14 00:00 [received]
PHST- 2015/05/28 00:00 [accepted]
PHST- 2015/08/12 06:00 [entrez]
PHST- 2015/08/12 06:00 [pubmed]
PHST- 2016/05/18 06:00 [medline]
PHST- 2015/06/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2015 Jun 1;8(6):7559-64. eCollection 2015.